Fomivirsen
Title: Fomivirsen
CAS Registry Number: 144245-52-3
CAS Name: d(P-Thio)(G-C-G-T-T-T-G-C-T-C-T-T-C-T-T-C-T-T-G-C-G)deoxyribonucleic acid
Molecular Formula: C204H263N63O114P20S20
Molecular Weight: 6682.40
Percent Composition: C 36.67%, H 3.97%, N 13.21%, O 27.29%, P 9.27%, S 9.60%
Literature References: Synthetic phosphorothioate antisense oligonucleotide designed to inhibit gene expression in human cytomegalovirus (CMV). Consists of 21 nucleotides in a sequence complementary to the specific portion of CMV messenger RNA which encodes regulatory proteins. Prepn: K. P. Anderson, K. G. Draper, WO 9203456; idem et al., US 5442049 (1992, 1995 both to Isis). Large scale synthesis: M. Andrade et al., Bioorg. Med. Chem. Lett. 4, 2017 (1994). Determn in pharmaceutical formulations by capillary gel electrophoresis: G. S. Srivatsa et al., J. Chromatogr. A 680, 469 (1994). Antiviral activity vs human CMV: R. F. Azad et al., Antimicrob. Agents Chemother. 37, 1945 (1993). Mechanism of action study: K. P. Anderson et al., ibid. 40, 2004 (1996). Pharmacokinetics: J. M. Leeds et al., Drug Metab. Dispos. 25, 921 (1997). Retinal toxicity study: M. Flores-Aguilar et al., J. Infect. Dis. 175, 1308 (1997). Review of pharmacology and therapeutic potential: J. Temsamani et al., Expert Opin. Invest. Drugs 6, 1157-1167 (1997). Series of articles on clinical experience for CMV retinitis in AIDS patients: Am. J. Ophthalmol. 133, 467-498 (2002).
 
Derivative Type: Sodium salt
CAS Registry Number: 160369-77-7
Manufacturers' Codes: ISIS-2922
Trademarks: Vitravene (Novartis)
Molecular Formula: C204H243N63Na20O114P20S20
Molecular Weight: 7122.04
Percent Composition: C 34.40%, H 3.44%, N 12.39%, Na 6.46%, O 25.61%, P 8.70%, S 9.00%
 
Therap-Cat: Antiviral.
Keywords: Antiviral; Polynucleotides.

Others monographs:
AcetolCaprylic AldehydeCy 3Cefcapene Pivoxil
CannabinolOil of CajeputAluminum AcetotartrateEnoxacin
TetradecamethylhexasiloxaneLH-RHCeftizoximeEthyl Chloride
CalicheamicinsStannous Oxalateα-Methyl-m-tyrosineSodium β-Sulfopropionitrile
©2016 DrugLead US FDA&EMEA